Watch CATX. Know when insiders buy.
One email the day a filing lands. Free.
Work order
41
WATCH · insiders 27, shorts 55
Insiders, 90 days
−$846K
net selling · 0 buys, 5 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $357.3MP/E —DIV YIELD —FCF YIELD -33.92%REV TTM —NET INCOME −$116.4MNET CASH $46.9M52W 2.05 – 5.65SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$29.3M | −$26.8M | — | -0.22 | −$20.6M | $14.2M | −$34.8M | Aug 10 |
| Q1 2026 · Mar 31 | — | — | — | −$28.3M | −$26.2M | — | -0.25 | −$31.5M | $6.9M | −$38.3M | Aug 10 |
| Q4 2025 · Dec 31derived | — | — | — | −$39.8M | −$37.5M | — | -0.51 | −$24.7M | $5.1M | −$29.7M | Mar 16 |
| Q3 2025 · Sep 30 | — | — | — | −$27.9M | −$26M | — | -0.35 | −$16.3M | $2M | −$18.3M | Nov 10 |
| Q2 2025 · Jun 30 | — | — | — | −$24M | −$21.5M | — | -0.29 | −$20M | $1M | −$21M | Aug 10 |
| Q1 2025 · Mar 31 | — | — | — | −$21.8M | −$18.2M | — | -0.25 | −$21.6M | $4.7M | −$26.2M | Aug 10 |
| Q4 2024 · Dec 31derived | — | — | — | −$45M | −$40.2M | — | -0.61 | −$26.6M | $14.6M | −$41.2M | Mar 16 |
| Q3 2024 · Sep 30 | — | — | — | −$18.6M | −$15.1M | — | -0.21 | $3.4M | $29.7M | −$26.3M | Nov 10 |
| Q2 2024 · Jun 30 | — | — | — | −$14.3M | −$11.7M | — | -0.18 | −$8.9M | $1M | −$9.9M | Nov 10 |
| Q1 2024 · Mar 31 | — | — | — | −$13M | −$12.3M | — | -0.25 | $13.8M | $9.1M | $4.8M | Nov 10 |
| Q4 2023 · Dec 31derived | — | — | — | −$11.7M | −$24.7M | — | -0.91 | −$9M | $89K | −$9.1M | Mar 28 |
| Q3 2023 · Sep 30 | $2.2M | — | 33.8% | −$9.8M | −$10.4M | — | -0.37 | −$10.1M | $227K | −$10.3M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$113.6M | −$103.1M | — | -1.40 | −$82.5M | $12.7M | −$95.2M | — | — |
| FY2024 · to Dec 31 | — | — | −$90.9M | −$79.3M | — | -1.23 | −$18.3M | $54.4M | −$72.7M | — | — |
| FY2023 · to Dec 31 | — | — | −$40.9M | −$46.5M | — | -1.74 | −$36.9M | $1.1M | −$38M | — | — |
| FY2022 · to Dec 31 | — | — | −$8.7M | −$10.8M | — | -0.08 | −$10.4M | $282K | −$10.7M | — | — |
| FY2022 · to Jun 30 | — | — | −$6.4M | −$7.3M | — | -0.05 | −$7.7M | $266K | −$8M | — | — |
| FY2021 · to Jun 30 | — | — | −$3.4M | −$3.4M | — | -0.03 | −$2.8M | $381K | −$3.2M | — | — |
Every number comes from Perspective Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.